Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

→ Build­ing off a sur­prise suc­cess with Mavyret in adults, Ab­b­Vie has nabbed an FDA ap­proval to mar­ket the he­pati­tis C drug for chil­dren ages 12 to 17. The drug — a com­bi­na­tion of gle­capre­vir and pi­brentasvir — racked up $3.438 bil­lion in net rev­enue for 2018, far ex­ceed­ing peak sales ex­pec­ta­tions. The OK was based on a tri­al of 47 HCV pa­tients with geno­types 1-4 sug­gest­ing a 100% cure rate, though it cov­ers all six geno­types.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER